



06-13-2003



102472500

T U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office
Docket No.

1 original documents or copy thereof.

Address of receiving party(ies)

To the Honorable Commission

1. Name of conveying party(ies):

Ube Industries, Ltd. (50% Interest)

Name: AstraZeneca UK, Ltd. (50% Interest)

Street Address: 15 Stanhope Gate

Additional name(s) of conveying party(ies) attached? ☐ Yes ☒ No

3. Nature of conveyance:

- ☒ Assignment ☐ Merger
☐ Security Agreement ☐ Change of Name
☐ Other

City: London State: Zip:

Country: England Postal Code: W1K 1LN

Additional name(s) & address(es) attached? ☐ Yes ☒ No

Execution Date(s):

50% Assignor: February 25, 2003

50% Assignee: May 1, 2003

4. Application number(s) or patent number(s);

If this document is being filed together with a new application, the filing date of the application is: 10/030.251

A. Patent Application No.(s)

B. Patent No.(s)

Additional numbers attached? ☐ Yes ☐ No

5. Name and address of party to whom correspondence concerning document should be mailed:

Attorney Name: Jeffrey L. Costellia

Firm Name: Nixon Peabody LLP

Internal Address: Suite 800

Street Address: 8180 Greensboro Drive,

City: McLean State: VA Zip: 22102

6. Total number of applications and patents involved: _____

7. Total fee (37 CFR 3.41).....\$40.00

- ☒ Enclosed
☐ Authorized to be charged to deposit account

8. Deposit account number:

19-2380

(Attach duplicate copy of this page if paying by deposit account)

DO NOT USE THIS SPACE

9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Jeffrey L. Costellia

Name of Person Signing

Signature

June 10, 2003

Date

Total number of pages including cover sheet, attachments, and documents: _____

CERTIFICATE OF MAILING OR TRANSMISSION [37 CFR 1.8(a)]

I hereby certify that this correspondence is being:

- ☐ deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Main Stop _____, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450
- ☐ transmitted by facsimile on the date shown below to the United States Patent and Trademark Office at (703) _____.

Date

Signature

Typed or printed name

Mail documents to be recorded with required cover sheet information to:

Mail Stop Assignment Recordation Services, Director of the US Patent and Trademark Office, P. O. Box 1450, Alexandria, VA 22313-1450

06/12/2003 LMUELLER 00000249 10030251

01 FC:8021

40.00 DP

NVA267257.1

PATENT
REEL: 014153 FRAME: 0501

ASSIGNMENT

WHEREAS, Ube Industries, Ltd., a Japanese company having offices at 1978-96, O-Aza Kogushi, Ube-Shi, Yamaguchi, 755-8633, Japan (Ube Industries), owns, by assignment, all right, title, and interest in U.S. Patent Application Serial No. 10/030,251, entitled Process for Preparing Dibenzothiazepine Derivatives, and any invention claimed therein; and

AstraZeneca UK, Ltd., a UK company, having offices at 15 Stanhope Gate, London, W1K 1LN, England (AstraZeneca), desires to own fifty-percent (50%) of Ube Industries's entire right, title, and interest in and to the invention, in all countries throughout the world, and in and to U.S. Patent Application Serial No. 10/030,251, and to any U.S. Letters Patent issuing therefrom.

NOW THEREFORE, be it known that, for good and valuable consideration, receipt of which is hereby acknowledged, Ube Industries hereby sells, assigns, transfers, and sets over to AstraZeneca, its lawful successors and assigns, fifty-percent (50%) of Ube Industries's entire right, title and interest in and to U.S. Patent Application Serial No. 10/030,251, any all Letters Patent of the United States that may be granted thereon, and all reissues, reexaminations, and continuations thereof; and Ube Industries hereby authorizes and requests the Commissioner of Patent and Trademarks of the United States to issue all Letters Patents for this invention to Ube Industries and AstraZeneca, and their respective successors and assigns, in accordance with the terms of this Assignment;

AND, Ube Industries and AstraZeneca, and their respective successors and assigns, agree to cooperate in maintaining U.S. Application Serial No. 10/030,251 and maintaining any Letters Patents that may granted thereon and to share equally in the expenses thereof. In the event of infringement by a third party of a jointly owned patent, either party may assert such patent and initiate an action for infringement thereof, provided, however, that the other party is given an opportunity in advance to join in the assertion and action and to share equally in the expenses and recoveries. Each party agrees to cooperate and assist the other in accordance with this provision, including joining the action to the extent necessary to permit the other party to maintain the suit. No party may grant a license under a jointly owned patent without the prior written consent of the other party, which consent will not be unreasonable withheld OR Each party shall be free to grant nonexclusive licenses under its interest in any jointly owned patent provided that the other party is given (a) notice to the identity of each such licensee, and (b) fifty-percent (50%) of all revenue received from each such license pursuant to such license.

IN TESTIMONY WHEREOF, each party has caused its authorized representative to execute this Agreement.

Ube Industries, Ltd.

By:

Toshio Nagasawa

Title: Senior Managing
Executive Officer

Date: February 25, 2003

AstraZeneca, Ltd.

By:

Kevin Bill

Title: Director IP Services

Date: 1 May 2023

This assignment should preferably be acknowledged before a United States Consul or Notary Public. If not, then the execution by the assignor, Ube Industries, Ltd., should be witnessed by at least two other persons who should sign below.

Witness Sachiyo Ono

Signature Sachiyo Ono

Witness Eiko Kawashima

Signature Eiko Kawashima

Witness _____

Signature _____